Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

4DMT

4DMT
2015 FOUNDED
IPO REG STATUS
51-60 EMPLOYEES
IPO LATEST DEAL TYPE (Announced)
$100M LATEST DEAL AMOUNT
16 INVESTORS
Description

Provider of a transformative discovery platform created for the treatment of serious and unmet medical conditions. The company's transformative gene therapeutic products unlock the full potential of gene therapy field and offers customized AAV vectors that can deliver genes to any cell in the body to eradicate disease, enabling clients to target specific patient tissues in a highly efficient and targeted fashion, while avoiding other tissues and resisting immune clearance (by pre-existing antibodies).

Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Drug Discovery
Biotechnology
Primary Office
  • 5858 Horton Street
  • Suite 455
  • Emeryville, CA 94608
  • United States

+1 (510) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore 4DMT’s full profile, request a free trial.

4DMT Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. IPO 30-Sep-2019 $100M 00000 Announced Generating Revenue/Not Profitable
8. Early Stage VC (Series B) 05-Sep-2018 0000 00000 Completed Generating Revenue
7. Grant 19-Sep-2017 000 000.00 Completed Startup
6. Grant 01-Sep-2016 00000 000.00 Completed Startup
5. Corporate 07-Jan-2016 000.00 Completed Startup
4. Early Stage VC (Series A1) 13-Oct-2015 000.00 000.00 Completed Startup
3. Early Stage VC (Series A) 12-Aug-2015 000 000 Completed Startup
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

4DMT Competitors (65)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Anokion Venture Capital-Backed Lausanne, Switzerland 00 00000 00000000000 00000
00000000 000000000 Formerly VC-backed Paris, France 00 00000 000000000 00000
000000000 Formerly VC-backed Tucson, AZ 00 000.00 000000&0 000.00
00000000 000000000 Formerly VC-backed Bedford, MA 000 00000 00000000 00000
00000000 000000000 Formerly VC-backed Dortmund, Germany 00 000.00 000000&0 000.00
To view this company’s complete list of competitors, request access »

4DMT Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
ArrowMark Partners Asset Manager Minority 000 0000 000000 0
Berkeley Catalyst Fund Venture Capital Minority 000 0000 000000 0
BVF Partners Hedge Fund Minority 000 0000 000000 0
Chiesi Ventures Corporate Venture Capital Minority 000 0000 000000 0
CureDuchenne Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

4DMT Executive Team (9)

Name Title Board
Seat
Contact
Info
David Kirn MD Chief Executive Officer, Chairman & Co-Founder
Theresa Janke Co-Founder & Chief Operating Officer
Fred Kamal Ph.D Chief Technology Officer
Melissa Kotterman Ph.D Vice President, Discovery & Engineering & Co-Founder
Leisa Johnson Vice President, Pre-Clinical R&D, Pharmacology & Toxicology Program Leader, Lung Therapeutic Area

1 Former Executive

You’re viewing 5 of 9 executives. Get the full list »

4DMT Board Members (11)

Name Representing Role Since Contact
Info
Charles Theuer MD Self Board Member 000 0000
David Kirn MD 4DMT Chief Executive Officer, Chairman & Co-Founder 000 0000
David Schaeffer Ph.D Self Board Member 000 0000
David Schaffer Ph.D Self Co-Founder, Chief Scientific Advisor & Board Member 000 0000
Deborah Marshall JD Sidley Austin Board Secretary 000 0000
You’re viewing 5 of 11 board members. Get the full list »